Randomized Split-Side Study Comparing Efficacy of Botulinum Toxin Type A Versus 0.9% Sodium Chloride in Scalp Psoriasis

    January 2018
    เกศกนิษฐ์ ธรรมคําภีร์
    Image of study
    TLDR Botulinum toxin type A significantly reduces scalp psoriasis severity compared to placebo.
    This randomized, split-side, double-blinded, placebo-controlled study evaluated the efficacy of botulinum toxin type A (62.5 units) versus 0.9% sodium chloride in treating scalp psoriasis in 14 patients. The primary endpoint was a 50% reduction in the modified Psoriasis Severity Index (mPSI50) at weeks 2, 4, 8, and 12. Results showed that botulinum toxin type A significantly reduced psoriasis severity compared to placebo, with mPSI50 achieved in 21%, 50%, 57%, and 43% of patients at the respective time points, versus 0%, 7%, 29%, and 14% for placebo. No serious side effects were reported, suggesting botulinum toxin type A as a potential adjuvant therapy for recalcitrant scalp psoriasis.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 15 results

    Similar Research

    5 / 588 results
      Subject Index

      research Subject Index

      March 2014 in “Journal of The American Academy of Dermatology”
      The document lists various dermatology topics, treatments, and diagnostic methods.
      Cutaneous Drug Reactions

      research Cutaneous Drug Reactions

      1 citations, January 2010 in “Elsevier eBooks”
      Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.
      Abstracts from the 2009 Annual Meeting of the Society for Pediatric Dermatology

      research Abstracts from the 2009 Annual Meeting of the Society for Pediatric Dermatology

      September 2009 in “Pediatric Dermatology”
      UVB is good for a skin condition in Asian kids, a lotion works for head lice, a drug helps with a skin blistering disorder, a foam reduces itchiness in skin inflammation, birthmarks can be more widespread, and criteria for a neurocutaneous disorder were agreed upon.